Regeneron - 2025 and beyond

So before we can really dissect the financial engine here, we have to look at the fuel, right? In 2025, Regeneron generated $14.34 billion in total revenues.

That's billion with a B.

Billion with a B.

But they aren't selling like thousands of different over the counter pills.

Their entire financial structure is built on just a few massive highly specialized biological therapies.

Yeah.

So the foundation of that 14.3 billion rests really heavily on two primary pillars.

First, you have their eye care franchise, which is ILEA and its high dose successor, ILEA HD.

These are treatments for severe eye conditions, mostly wet age related macular degeneration.

Right.

And we're talking about a disease where abnormal blood vessels basically grow underneath the retina.

They leak fluid and they cause blindness.

Wow.

Yeah.

So ELEA is an anti-VEGF inhibitor.

And this sounds intense.

Literally injected into the eye.

Oh, man.

Yeah.

But it blocks a specific protein to stop those blood vessels from growing and leaking.

It's an incredibly targeted mechanism.

And then you look at their other major pillar, which is on the immunology side, and that's dominated by a drug called dupixent.

Yes.

Dupixent is an absolute powerhouse.

The 10K shows it's massive.

So before we can really dissect the financial engine here, we have to look at the fuel, right? In 2025, Regeneron generated $14.34 billion in total revenues.

That's billion with a B.

Billion with a B.

But they aren't selling like thousands of different over the counter pills.

Their entire financial structure is built on just a few massive highly specialized biological therapies.

Yeah.

So the foundation of that 14.3 billion rests really heavily on two primary pillars.

First, you have their eye care franchise, which is ILEA and its high dose successor, ILEA HD.

These are treatments for severe eye conditions, mostly wet age related macular degeneration.

Right.

And we're talking about a disease where abnormal blood vessels basically grow underneath the retina.

They leak fluid and they cause blindness.

Wow.

Yeah.

So ELEA is an anti-VEGF inhibitor.

And this sounds intense.

Literally injected into the eye.

Oh, man.

Yeah.

But it blocks a specific protein to stop those blood vessels from growing and leaking.

It's an incredibly targeted mechanism.

And then you look at their other major pillar, which is on the immunology side, and that's dominated by a drug called dupixent.

Yes.

Dupixent is an absolute powerhouse.

The 10K shows it's massive.